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Abstract Guidelines recommend long-term use of beta-
blockers (BB), statins, and angiotensin-converting-enzyme-
inhibitors or angiotensin-receptor-blockers (ACEI/ARB)
after myocardial infarction (MI), but data on their use after
dischargearescarce.FromAustriansicknessfundsclaims,we
identiﬁed all acute MI patients who were discharged within
30 days and who survived C120 days after MI in 2004. We
ascertained outpatient use of ACEI/ARBs, BBs, statins, and
aspirin from all ﬁlled prescriptions between discharge and
120 dayspostMI.Comorbiditieswereascertainedfromuseof
indicator drugs during the preceding year. Multivariate
logistic regression was used to evaluate the independent
determinants of study drug use. We evaluated 4,105 MI
patients,whosemeanagewas68.8(±13.2)years;59.5%were
men. Within 120 days after MI, 67% ﬁlled prescriptions for
ACE/ARBs, 74% for BBs, and 67% for statin. While 41%
received all these classes and 34% two, 25% of patients
received only one or none of these drugs. Older age and
presence of severe mental illness were associated with lower
use of all drug classes. Diabetics had greater ACEI/ARB use.
Fewer BBs were used in patients with obstructive lung dis-
ease. Statin use was lower in patients using treatment for
congestive heart failure (all P\0.001). We conclude that
recommended medications were underused in Austrian MI
survivors. Quality indicators should be established and inter-
ventions be implemented to ensure maximum secondary
prevention after MI.
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Introduction
Cardiovascular disease is among the leading causes of
premature death and morbidity in most Western societies.
Fortunately, the prognosis of myocardial infarction(MI)has
steadily improved over the past decades: case fatality after
MI has decreased and long-term survival has increased
[1–3], likely due to the introduction and increasing avail-
ability and use of acute invasive and non-invasive
interventions as well as the introduction of powerful
medications for secondary prevention [4].
Among the medications for long-term secondary inter-
vention, aspirin, beta-receptor blockers (BB), 3-hydroxy-
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angiotensin converting enzyme (ACE) inhibitors have
drawn the most attention. More recently, angiotensin
receptor blockers (ARB) have become available for use in
those patients who develop adverse events from ACE
inhibitors; ACE inhibitors and ARBs have been shown to
be equally efﬁcacious and effective after MI [5–7].
All these interventions are highly efﬁcacious in reducing
the recurrence of MI, the subsequent use of coronary
interventions, or the risk of death, and have been demon-
strated to be highly attractive economic investments from a
societal perspective [8–11]. Practice guidelines recommend
the use of these medications for secondary prevention in
patients with unstable angina or MI, regardless whether the
MI is associated with ST-elevation [12–14]. Considerable
variation has been observed, however, in the use of these
beneﬁcial interventions [3, 15–17], which has prompted the
establishment of quality of care indicators in some countries
with the goal to monitor appropriate use of these interven-
tions during hospitalization, at discharge, and during
outpatient follow-up after such an event [18–20]. Most
relevant in the long run, however, is the outpatient use of
these medications after discharge from MI. Several studies
have indicated that these drugs are underused for secondary
prevention. Most of these investigations were conducted in
North America [21–23] and in Europe [24–29]. No such
systematic assessment has been conducted in the Austrian
health care system except for a small local study [30]. We
sought to ﬁll this void by studying proportions of BB, statin
and ACE inhibitor or ARB use after MI in a large period
cross-section of Austrian MI patients.
Methods
Data sources
Austria is a social welfare state that mandates universal
health care to its residents [31]. Patients are assigned
membership in one of several sickness funds dependent on
their type and location of current or former employment.
At the time covered by this study, there were 20 sickness
funds in Austria; among those, the 9 provincial sickness
funds covering more than three quarters of all residents (6.2
Mio. of 8.2 Mio. overall; data from 2004). Most inpatient
and outpatient medical services are covered and each ser-
vice encounter generates a claim to the health care system.
Inpatient services are not paid directly by sickness funds,
but by a separate entity, which, however, is partly funded
by these. Thus, sickness funds are also informed about each
encountered inpatient care. Similarly to most western
health care systems, datasets provided by hospitals contain
diagnosis codes, admission and discharge dates. Access to
prescription drugs is equal across sickness funds and all
medications that are deemed efﬁcacious by a national panel
are reimbursed. The copayment for medicines per package
was €4.25 in 2003, €4.35 in 2004 and €4.45 in 2005.
Packages of chronic medications usually contain 28, 30, or
50 pills. Sickness fund premiums, other coinsurance and
copayments vary slightly, and indigent patients can apply
for waiver of the usually modest copayment for prescrip-
tion drugs. Few medications are subject to prior
authorization by the sickness funds. Prescription claims
contain a unique identiﬁer for the speciﬁc drug, the dose,
and the quantity dispensed.
Study population
For the purpose of this study, we used the complete claims
data of individuals covered by several of these sickness
funds: the provincial sickness funds (Gebietskrankenkasse)
of Vienna, Lower Austria, Upper Austria, Styria, Bur-
genland, and Carinthia, as well as the funds covering all
federal employees (Bundesversicherungsanstalt, BVA) and
farmers (Sozialversicherung der Bauern, SVB), respec-
tively. Cumulatively, these sickness funds cover
approximately 6.1 million members of the total Austrian
insured population of 8.2 million. Each sickness fund
separately identiﬁed from their insurance claims all
patients who were hospitalized and discharged with a
primary diagnosis of acute MI in 2004 (International
Classiﬁcation of Diseases, ICD-9: 410.xx; ICD-10: I21)
and provided us with their relevant anonymized health
care claims data covering the period from January 1, 2003
to June 30, 2005. We only studied each patient’s ﬁrst
hospitalization for MI (including direct transfers from one
hospital to another) and required that the admission date
be between January 1, and December 31, 2004. We
retained only those patients whose hospitalization excee-
ded 3 days and who were admitted at an acute care
hospital. Including patients who were hospitalized\4 days
would open up the possibility of wrongly selecting patients
into the study sample who had not experienced an MI
(e.g., whose MI was ruled out or patients who were
admitted for a diagnostic or therapeutic intervention and
still coded for acute MI). Our approach of identifying
patients with MI has been validated in similar claims data
and found to be highly accurate (positive predictive value:
94%) [32]. Since we were interested in medication use
after MI, we generated a uniform outcomes ascertainment
window and required all patients to be discharged within
30 days and to have survived for C120 days from their
initial admission date (=index date). We also excluded
those patients whose hospitalization occurred at a non-
acute care hospital.
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after myocardial infarction
From all ﬁlled prescriptions, we recorded out-of-hospital
use of several medications between date of discharge and
120 days after MI admission: aspirin, beta-blockers, stat-
ins, and ACE inhibitors or ARBs. We also assessed the
total number of distinct medications that patients received
among statin, BB, and ACE inhibitor/ARB (minimum 0;
maximum 3). Since aspirin was available for a price that
was below the amount of the drug copayment (€4.35), it is
possible that insurance claims data may lead to under-
ascertainment of aspirin use. Thus, we decided to investi-
gate aspirin separately, and only among patients who had
their copayment waived based on income grounds. These
indigent patients had a clear economic incentive to ﬁll
prescriptions for aspirin via the prescription route, thus
generating a claim to the sickness fund.
Covariates
We created variables indicating each patient’s age in 2004,
gender, the length of stay for their index admission, and
whether a patient had their prescription copayments waived
during the study period (NoCopay vs. Copay). Since claims
from outpatient encounters did not contain any diagnosis
codes, we ascertained medication use in the 365 days prior
to the index date as proxies for several comorbidities using
the anatomic therapeutic chemical (ATC) classiﬁcation
system: oral antidiabetic drugs, insulin, antigout medica-
tions, several cardiovascular drug classes (alpha blockers,
BBs, calcium channel blockers, ACE inhibitors, ARBs,
other antihypertensives, diuretics, nitrates, digitalis, vita-
min K-antagonist, statins, ﬁbrates), medications indicated
for asthma or chronic obstructive pulmonary disease
(COPD; inhaled corticosteroids, beta-receptor agonists),
drugs reducing gastro-esophageal reﬂux or ulcer disease
(histamine-H2-blockers, proton pump inhibitors, sucralfate,
antacids), pain medications (including non-steroidal anti
inﬂammatory drugs, selective COX-2 inhibitors, opioids,
and others), oral corticosteroids, and several psychoactive
drug classes (benzodiazepines or anxiolytics, antidepres-
sants, antipsychotics). We also recorded the number of
hospital days during the year prior to the index date (cat-
egorized into: no hospitalization, 1–7, 8–21, and
[21 days).
Statistical analysis
We plotted the unadjusted proportions of medication use
for the overall population as well as by copayment status
along with the corresponding 95% conﬁdence intervals
(CIs). We then used univariate and multivariate logistic
regression to estimate the crude and multivariate adjusted
odds of receiving a given study medication. Since none
of our outcomes were rare, we were able to create full
multivariate models that included all variables regardless
of their statistical signiﬁcance. In large datasets where
outcomes are not rare, full multivariate models are
superior to parsimonious models, because they provide
better control for residual confounding compared to more
restricted models. Odds ratios (OR) were presented with
their 95% CIs. Additionally, we showed the population
distribution of the number of different study drug classes
received among statin, BB, and ACE inhibitor/ARB
(minimum 0; maximum 3). Multivariate ordinal logistic
regression and linear regression were used to model the
associations between covariates and the number of drugs
received. All analyses were conducted in the full ﬁnal
study population as well as after restriction to new users
of each study drug, i.e. patients who had not received the
respective study drug in the year prior to admission for
MI. We used the SAS for Windows (release 9.2) soft-
ware for all statistical analyses (The SAS Institute, Cary,
NC).
Results
Study population
We ﬁrst identiﬁed 8,416 hospitalizations with a discharge
diagnosis indicating an MI. After excluding all repeat MI
hospitalizations and those that occurred before or after
2004 (N = 1,977; 23.5%), we also excluded those patients
who died within 120 days after admission for MI
(N = 1,221; 14.5%). After further restricting the sample to
those patients whose index hospitalization was C4, but
B30 days and excluding admissions at non-acute care
hospitals, we obtained a ﬁnal study sample of 4,105
patients (48.8% of the original hospitalization sample
drawn). The mean age was 68.8 years (standard deviation,
SD: ±13.2), and 2,442 (59.5%) patients were men. Age
differed considerably by gender: men (median: 66 years,
interquartile range: 56–75) were substantially younger than
women (median: 76 years, interquartile range: 67–82;
P\0.001). Overall, 654 (15.9%) had their prescription
copayments waived on the grounds of low income
(Table 1). On average, they had been hospitalized for 6.7
(±14.7) days in the year prior to their MI and the mean
length of stay for their index admission was 10.9 (±5.3)
days. The proportions of selected prescription drugs used in
the year prior to admission for MI are listed in detail in
Table 1.
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Within 120 days of their admission for MI, 3,037 (74.0%;
95% CI: 72.6–75.3%) patients ﬁlled a prescription for a
BB, 2,745 (66.9%; 95% CI: 65.5–68.3%) for an ACE
inhibitor or an ARB, and 2,736 (66.7%; 95% CI: 65.3–
68.1%) received a statin (Fig. 1). Indigent patients who
were not required to pay a copayment received more ACE
inhibitors or ARBs (74 vs. 65.5%; P\0.001), and slightly
fewer statins (63.2 vs. 67.2%; P = 0.03), while the
proportion of BB use was similar to patients without such a
waiver (P = 0.86).
The distribution of number of distinct drug classes
received in this population was as follows: 1,692 patients
(41.2%) received a BB, statin, and an ACE inhibitor or
ARB, while 1,391 (33.9%) received two of these drugs. Six
hundred and sixty (16.1%) patients received only one of the
study drugs whereas 362 (8.8%) patients received none of
these medications for secondary prevention at all. This
distribution did not differ between patients with vs. without
copayment requirement (P = 0.33). The number of drugs
received was slightly higher among men compared to
women (2.1 vs. 2.0; P = 0.02) and decreased with higher
age (P\0.001). Among the 654 patients with waived
copayment, 464 (71%) ﬁlled a prescription for aspirin
within 120 days of admission for MI.
Independent predictors of study medication use
Age was an independent predictor of recommended med-
ication use after MI: compared to patients younger than
50 years, those between 70 and 89 years had 48% greater
odds of receiving ACE inhibitors or ARBs (OR: 1.48),
whereas the oldest patients (C90 years old) were least
likely to receive these drugs (OR: 0.73; Table 2). Similarly,
these oldest patients were also markedly less likely to
receive BBs and statins (Tables 3 and 4). Number of days
spent in the hospital in the year preceding the MI admis-
sion, a marker of preexisting comorbidity, was consistently
and inversely associated with lower use of all these rec-
ommended medications (all P for trend \0.001). Patients
who had their copayments waived were more likely to ﬁll a
prescription for an ACE inhibitor or an ARB after dis-
charge from MI than patients with copayment required
(OR: 1.35; 95% CI: 1.10–1.67), but BB or statin use did not
differ between these groups. Angiotensin converting
enzyme inhibitor or ARB use was further independently
associated with previous calcium channel blocker use, use
of an oral antidiabetic drug, and prior use of antipsychotic
drugs (Table 2). Beta-receptor blockers were more likely to
be used in patients who had used other antihypertensive
Table 1 Characteristics of study population (N = 4,105)
Variable Count (%) or mean (±SD)
Age 68.8 (±13.2)
\50 years 402 (9.8)
50–69 years 1,515 (36.9)
70–89 years 1,225 (29.8)
C90 years 963 (23.5)
Male gender 2,442 (59.5)
Length of stay 10.9 (±5.3)
Days of hospitalization in prior year 6.7 (±14.7)
None 2,500 (60.9)
1–7 days 595 (14.5)
8–21 days 612 (14.9)
C21 days 398 (9.7)
Copayment waived 654 (15.9%)
Previous medication use
Alpha blocker 243 (5.9)
ACE-inhibitor or ARB 1,853 (45.1)
Beta-blocker 1,454 (35.4)
Calcium channel blocker 809 (19.7)
Other antihypertensive 734 (18.0)
Diuretic 927 (22.6)
Nitrate 1,032 (25.1)
Digitalis 347 (8.5)
Acetylsalicylic acid 1,169 (28.5)
Clopidogrel or Ticlopidine 385 (9.4)
Vitamin K-antagonist 249 (6.1)
Statin 1,043 (25.4)
Fibrate 116 (2.8)
Oral hypoglycemic 620 (15.1)
Insulin 265 (6.5)
Uric acid lowering drug 559 (13.6)
Pain medication 1,934 (47.1)
Gastroprotective drug 1,584 (38.6)
Asthma/COPD 610 (14.9)
Corticosteroid 379 (9.2)
Benzodiazepine or anxiolytic 491 (12.0)
Antidepressant 623 (15.2)
Antipsychotics 190 (4.6)
0%
10%
20%
30%
40%
50%
60%
70%
80%
ACEI/ARB BB Statin Aspirin
All Copayment No Copayment
Fig. 1 Proportions of medication use after myocardial infarction
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123medications prior to MI (Table 3). Lower use of BBs was
observed in patients who had received diuretics, vitamin K-
antagonist, insulin, antipsychotics, as well as in those
patients who received inhaled medications for asthma or
COPD (Table 3). Medications that were inversely associ-
ated with statin use were diuretics, digitalis, clopidogrel,
vitamin K-antagonist, and antipsychotics (Table 4).
Naturally, prior use of a medication class was highly
predictive of use of that class after MI in the full study
population. Results from the analyses restricted to new
users of each study drug were very similar to the full
population analyses, albeit with wider conﬁdence intervals
(Tables 2–4). Analyses of independent predictors of num-
ber of recommended drugs received using linear or ordinal
logistic regression conﬁrmed what could be gleaned from
the analyses of each drug class: older age, more hospital
days in the previous year, indicator drugs for severe heart
failure (digitalis, diuretics, vitamin K-antagonist), and
antipsychotic use were all independently associated with
fewer recommended medications received (results not
shown). Gender, however, was not independently associ-
ated with number of medications received.
Discussion
In a large population-based study of patients who experi-
enced an acute MI in Austria, we found that ambulatory
use of several recommended medications after discharge
was suboptimal. Within 120 days after their MI, only 74%
patients received a BB, 67% a statin, and 67% ﬁlled a
prescription for an ACE inhibitor or ARB. Only 41% of
Table 2 Independent
determinants of ACE-inhibitor
or ARB use
* P for trend\0.001
Variable All patients (N = 4,105) New users (N = 2,252)
OR 95% CI OR 95% CI
Age \50 – Referent – Referent
50–69 1.19 0.96–1.49 1.23 0.96–1.58
70–89 1.48 1.19–1.85 1.54 1.19–2.00
C90 0.73 0.59–0.90 0.79 0.60–1.03
Male gender 1.07 0.91–1.25 1.19 0.98–1.44
Length of stay 1.02 1.00–1.03 1.03 1.01–1.05
Hospital days* 0 – Referent – Referent
1–7 0.68 0.56–0.84 0.62 0.49–0.80
8–21 0.79 0.63–0.99 0.68 0.51–0.91
[21 0.51 0.39–0.68 0.53 0.35–0.79
Copayment waived 1.35 1.10–1.67 1.34 1.03–1.74
Alpha-blocker 1.07 0.75–1.53 1.27 0.73–2.20
ACE-inhibitor or ARB 5.67 4.74–6.78 – –
Beta-blocker 1.12 0.94–1.33 1.16 0.93–1.45
Calcium channel-blocker 1.35 1.10–1.66 1.34 1.01–1.79
Other anti-hypertensive agents 0.99 0.80–1.21 1.12 0.85–1.47
Diuretic 0.85 0.68–1.05 0.87 0.65–1.18
Nitrate 0.88 0.72–1.07 0.82 0.63–1.08
Digitalis 1.15 0.84–1.57 1.04 0.65–1.65
Aspirin 0.89 0.74–1.07 0.91 0.70–1.18
Clopidogrel 0.90 0.68–1.20 0.73 0.46–1.15
Vitamin K-antagonist 0.99 0.70–1.41 1.10 0.65–1.87
Statin 1.12 0.92–1.38 0.84 0.63–1.11
Fibrate 1.21 0.76–1.93 1.00 0.56–1.77
Oral antidiabetic 1.26 1.00–1.58 1.06 0.79–1.44
Insulin 1.02 0.73–1.44 1.20 0.68–2.10
Asthma/COPD 1.07 0.86–1.34 1.10 0.83–1.47
Benzodiazepines/anxiolytics 1.06 0.83–1.36 1.16 0.83–1.62
Antidepressants 0.87 0.70–1.09 0.85 0.64–1.13
Antipsychotics 0.64 0.45–0.91 0.65 0.41–1.04
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123patients received all three interventions, while 25% of
patients received only one of these beneﬁcial drugs or even
none at all. Underuse of these medications is unfortunate
from both a patient’s and a societal perspective: while
optimal secondary prevention including these drugs pro-
longs the expected lifespan of a patient after MI, use of
these interventions constitutes an attractive allocation of
scarce economic resources. Thus, considerable room for
improvement is present in the care of patients after MI in
Austria, and interventions ought to be targeted towards
increasing the prescribing and use of these medications.
While this is the ﬁrst large-scale study of the quality of
post-MI care in Austria, similar investigations have been
conducted in other countries. The most relevant compari-
son can be drawn with results from the EUROASPIRE
studies [27–29]. These studies, three waves have been
conducted to date, used surveys to evaluate coronary care
in 9 (EUROASPIRE I), 15 (EUROASPIRE II), and 22
(EUROASPIRE III) countries, respectively; Austria did not
participate in either of these. The most recent data available
are from EUROASPIRE II, which covered the years 1999/
2000 [28]. Medication use was assessed at admission,
discharge (abstracted from charts), and at least 6 months
(from patient interview) after the acute admission or pro-
cedure. While some variation was observed across
countries, data speciﬁcally for after MI drug use was only
reported in aggregate across countries. Approximately 74%
of MI patients received a BB at discharge and 68%
[6 months after the event; these proportions are similar to
the 74% observed in our study. For ACEI, the proportions
at discharge and [6 months after the event were 49 and
45%, respectively, considerably lower than the 67%
observed in Austria. It is unclear, however, whether ARB
use was regarded equivalent to ACEIs and included in this
Table 3 Independent
determinants of beta-blocker
use
* P for trend\0.001
Variable All patients (N = 4,105) New users (N = 2,651)
OR 95% CI OR 95% CI
Age \50 – Referent – Referent
50–69 1.25 0.98–1.60 1.21 0.93–1.59
70–89 1.05 0.83–1.33 1.14 0.87–1.47
C90 0.62 0.51–0.76 0.54 0.43–0.69
Male gender 1.14 0.97–1.35 1.19 0.98–1.43
Length of stay 1.00 0.98–1.01 1.00 0.98–1.01
Hospital days * 0 – Referent – Referent
1–7 0.92 0.74–1.15 0.85 0.66–1.08
8–21 0.77 0.61–0.96 0.78 0.60–1.02
[21 0.57 0.44–0.75 0.61 0.43–0.84
Copayment waived 1.09 0.89–1.35 1.19 0.93–1.53
Alpha-blocker 1.54 1.07–2.20 1.73 1.12–2.67
ACE-inhibitor or ARB 1.22 1.02–1.45 1.16 0.94–1.41
Beta-blocker 4.36 3.55–5.35 – –
Calcium channel-blocker 1.29 1.05–1.59 1.49 1.16–1.90
Other anti-hypertensive agents 0.83 0.68–1.01 0.87 0.69–1.10
Diuretic 0.80 0.65–0.98 0.77 0.60–0.99
Nitrate 1.03 0.84–1.26 1.04 0.81–1.33
Digitalis 0.79 0.60–1.04 0.68 0.48–0.96
Aspirin 0.96 0.79–1.16 0.88 0.70–1.12
Clopidogrel 0.79 0.59–1.07 0.65 0.43–0.97
Vitamin K-antagonist 0.67 0.49–0.93 0.44 0.29–0.66
Statin 0.94 0.76–1.16 0.85 0.67–1.10
Fibrate 1.14 0.70–1.86 1.21 0.65–2.25
Oral antidiabetic 1.06 0.85–1.32 1.07 0.82–1.39
Insulin 0.72 0.53–0.98 0.78 0.52–1.16
Asthma/COPD 0.67 0.55–0.83 0.63 0.49–0.80
Benzodiazepines/anxiolytics 1.33 1.04–1.71 1.27 0.94–1.72
Antidepressants 0.88 0.71–1.09 0.96 0.74–1.24
Antipsychotics 0.71 0.51–1.00 0.74 0.50–1.09
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123quality measure in the EUROASPIRE study. Lipid-lower-
ing drugs were prescribed to 42% of patients at discharge
and used by 60% at[6 months after the event, compared
to 67% in our study [28].
A comparison of these reports, however, needs to be
conducted with caution. Considerable differences exist
between these and other studies, especially in their popu-
lation selection criteria, ascertainment of medication use,
and the year(s) studied. Several studies, speciﬁcally from
the United States and Canada, investigated medication use
only in older patients ([65 years) [33]. Results from
elderly populations cannot be compared with ﬁndings from
the general population, since age is a strong predictor of
preventive medication use. Studies that measured medica-
tion use using discharge notes are likely to overestimate
medication use, because patients may not have received a
prescription or had chosen to not ﬁll it. The increasing use
of the study medications also needs to be taken into con-
sideration and, in this respect, older reports considerably
vary with recent ones. To this point, Gislason et al. [24]
studied MI patients in Denmark and found that the pro-
portion of patients who received an ACE inhibitor
increased from 25% in 1995 to 36% in 2002. Similarly, use
of BB increased from 38% to 68% during that time. This
study differs from ours in that drug use was ascertained
within 30 days following the discharge date from MI.
While BB use is roughly similar to our ﬁndings, the use of
ACE inhibitor was substantially lower in that Danish
cohort. Statin or aspirin use was not part of that study, but a
separate study using the same Danish database focused on
this aspect of post MI care. In this report, statin use was
ascertained within 6 months of discharge and increased
from 13% in 1995 to 61% in 2002 [34]. This percentage is
similar to the statin use of 67% in our Austrian sample,
Table 4 Independent
determinants of statin use
* P for trend\0.001
Variable All patients (N = 4,105) New users (N = 3,062)
OR 95% CI OR 95% CI
Age \50 – Referent – Referent
50–69 1.38 1.09–1.76 1.40 1.09–1.81
70–89 1.08 0.86–1.36 1.09 0.85–1.39
C90 0.39 0.32–0.47 0.37 0.30–0.46
Male gender 1.10 0.94–1.29 1.13 0.95–1.35
Length of stay 0.98 0.97–0.99 0.99 0.97–1.00
Hospital days* 0 – Referent – Referent
1–7 0.88 0.71–1.09 0.82 0.66–1.04
8–21 0.68 0.55–0.85 0.68 0.53–0.87
[21 0.48 0.37–0.63 0.47 0.34–0.65
Copayment waived 1.09 0.89–1.34 1.07 0.85–1.34
Alpha-blocker 0.89 0.65–1.22 1.04 0.72–1.51
ACE-inhibitor or ARB 0.98 0.82–1.16 1.04 0.86–1.25
Beta-blocker 1.08 0.91–1.29 1.07 0.88–1.30
Calcium channel-blocker 1.01 0.83–1.23 0.98 0.79–1.23
Other anti-hypertensive agents 0.97 0.80–1.18 0.97 0.78–1.21
Diuretic 0.82 0.67–1.00 0.79 0.63–1.00
Nitrate 0.94 0.77–1.14 0.96 0.77–1.21
Digitalis 0.60 0.46–0.80 0.51 0.37–0.72
Aspirin 0.85 0.71–1.03 0.74 0.60–0.92
Clopidogrel 0.70 0.51–0.94 0.61 0.40–0.94
Vitamin K-antagonist 0.62 0.45–0.85 0.52 0.35–0.78
Statin 6.39 5.03–8.11 – –
Fibrate 2.24 1.36–3.70 2.31 1.35–3.97
Oral antidiabetic 0.95 0.77–1.18 0.98 0.77–1.26
Insulin 0.76 0.56–1.04 0.71 0.48–1.05
Asthma/COPD 0.87 0.71–1.07 0.84 0.66–1.06
Benzodiazepines/anxiolytics 0.89 0.70–1.12 0.94 0.72–1.22
Antidepressants 1.13 0.91–1.40 1.08 0.85–1.39
Antipsychotics 0.48 0.34–0.68 0.53 0.36–0.79
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123given that our data are slightly more recent; we did,
however, use a shorter ascertainment window. Another
report studied the use of preventive medications after MI in
The Netherlands [26]. The authors conﬁrmed a trend
towards increased use of all drug classes from 1991 to
2000, with ACE inhibitor being dispensed to 44%, BB to
76%, and statins to 58% in the most recent study year
(2000). Use of these medications was ascertained within
30 days after discharge, but patients were not required to
survive for a minimum number of days after discharge to
be eligible for study. Taking these study design differences
into account, it appears that more patients received a BB
after discharge in the Netherlands compared to Austria.
Interestingly, neither the Dutch, nor the Danish study took
ARB use into consideration as an established substitute for
ACE inhibitors. Similarly, data from EUROASPIRE I and
II conﬁrms increasing use these preventive medications
[29].
In the present study, we also identiﬁed several predictors
of use for the study medications. In general, patients
C90 years of age were substantially less likely to receive
these recommended medications than younger patients.
Similar evidence for under-treatment among the elderly
was also found in other countries [24]. This behavior may
constitute general treatment bias against very old patients,
or reﬂect that these patients may not live long enough to
reap the beneﬁts of long-term preventive interventions.
Indeed, speciﬁc evidence on the efﬁcacy and cost-effec-
tiveness of the study medications in very old patients is
lacking. In general, old patients were excluded from par-
ticipation in virtually all efﬁcacy trials on which current
clinical practice recommendations are based. Only the
PROspective Study of Pravastatin in the Elderly at Risk
(PROSPER) trial has addressed this issue and speciﬁcally
studied older individuals. PROSPER demonstrated that
statins are efﬁcacious in prevention of coronary events in
older patients, but the participants in PROSPER were still
‘‘only’’ 70–82 years at enrollment [35]. Further, statin
therapy has been shown to be cost-effective in 75–84 years
old patients [36]. We found that those indigent patients
who had their copayment waived had at least the same
level of medication use compared to relatively more
afﬂuent patients who were responsible for the copayment
portion of their prescription (€4.35), thus indicating that
such a waiver successfully removed the economic barriers
to ﬁlling these prescriptions. Of note, patients whose
copayment was waived were more likely to be women and
previous recipients of antipsychotic drugs, but otherwise
similar to those who were required to pay a copayment
(detailed results not shown).
The number of hospital days in the year prior to MI was
a strong negative predictor of medication use for all clas-
ses. This might reﬂect greater comorbidity or frailty in
these patients, which both have been associated with lower
use of and persistence with preventive medications. Simi-
larly, patients receiving antipsychotic drugs had a lower
likelihood to receive the study medications, likely indi-
cating treatment bias regarding the mentally diseased.
Beta-blocker use was signiﬁcantly lower among patients
who received any drugs for inhalation that are indicated in
asthma or COPD, a plausible pattern, which may reﬂect
presence of a relative contraindication or intolerance by the
patient. Indeed, among patients without previous use of
such asthma or COPD drugs (N = 3,495), BB use after MI
was 75.4% (rather than 74.0% in the overall population), an
only slightly higher proportion with respect to the goal of
appropriately treating all patients free from contraindica-
tions. Statins were less likely to be used in patients who
had previously used diuretics, digitalis, or coumadin, pos-
sibly indicating congestive heart failure or atrial ﬁbrillation
and thus, worse prognosis.
In theory, and barring presence of any absolute contra-
indications, 100% of patients could receive each of these
medications. Clearly, the actual proportion that could be
attained in practice is lower than that, since some patients
will have an absolute contraindication for any given drug.
For ACEI/ARBs, this number would be very low, since the
only absolute contraindication (other than pregnancy) is
history of angioedema, whose incidence is below 1%
among new ACEI users [37]. Beyond this, relative con-
traindications may exist such as hyperkalemia or advanced
chronic kidney disease, but in most patients, at least a low-
dose trial of an ACEI/ARB should be attempted with
appropriate clinical and laboratory monitoring in place,
possibly in combination with a loop diuretic. Similarly, for
statins, practically every one should receive this treatment
and absolute contraindications are either very rare (active
liver disease) or not to be expected in this MI population
(pregnancy, lactation). Thus, at least an attempt at using
statins and ACEI/ARB in post-MI patients can be expected
in probably [95% of patients. The situation is slightly
different with BBs, since more contraindications exist
whose classiﬁcation as absolute vs. relative are uncertain
[38]. Cardiogenic shock, hypotension, and certain brady-
cardic arrhythmias untreated with a pacemaker certainly
constitute absolute contraindications, whereas a treatment
attempt in patients with stable obstructive lung disease
should be conducted. From our dataset, it is difﬁcult to
ascertain most of these conditions, but when eliminating all
patients who had received inhalative corticosteroids or beta
mimetics, the percentage of BB users increased slightly to
75.4% from 74.0% in the overall population.
This report needs to be read with several limitations in
mind. Aspirin was available at a price below the copay-
ment for prescription medications. Thus, aspirin use may
be underascertained in non-indigent patients. We were,
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123however, able to assess aspirin use in those patients who
had their copayment waived and found that 71% of patients
received this drug. While we cannot be certain that medi-
cations received in the pharmacy were actually taken by
these patients, our way of ascertaining medication use is
superior to other methods. Compared to notes in medical
charts, patients may not ﬁll the prescriptions they were
given. In surveys, patients may report what they perceive
as being desirable rather than their actual behavior. Both
methods, may lead to inaccurately optimistic estimates of
medication use. In our study, comorbidities were not
ascertained from diagnosis codes, but rather from typical
medications that are given for several comorbidities. It has
been shown that the information from diagnosis codes and
from medication claims provides only marginally inferior
confounding control in administrative datasets [39]. On a
similar note, we were unable to ascertain reliable infor-
mation on contraindications for the study drugs. Since most
of these contraindications are relative rather than absolute
contraindications [37, 38] this aspect may be of minor
importance. While not fully population based, our data
differ from other studies in that a wide range of hospitals
and typical care settings were studied rather than single
departments in predominantly academic medical centers.
We consider our data generalizable to the population level,
since three quarters of the Austrian population were
included in the study, and the preponderance of patients
omitted (1.2 Mio.; data from 2004) was excluded because
they lived in the three Western provinces (Salzburg, Tyrol,
Vorarlberg), whose sickness funds did not participate in
our data collection effort. The remaining patients that we
were unable to capture were members of very small cor-
porate sickness funds, railroad and mining workers, as well
as self-employed individuals; all those, however, received
care at the same hospitals and by the same physicians as the
enrolled patients. Finally, the analytical dataset did not
contain linkable pseudoanonymized hospital identiﬁers.
Thus, we were unable to study variations in treatment
behavior across the provider level. It has been shown that
provider preference can be a stronger determinant of
treatment received than actual patient level indications
[40].
In summary, we provide evidence for underuse of sev-
eral recommended medications after MI as recently as
2004 in the Austrian healthcare system. Our observations
are in line with ﬁndings from other European and North
American healthcare systems, despite the differences in
data collection and time period studied. Educational efforts
need to be directed at both physicians and patients, and the
implementation of quality indicators should be considered.
Maximizing secondary prevention after MI is highly
desirable from an individual patient and the societal
perspective.
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